Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study.

ABSTRACT:

SUBMITTER: Chalopin T 

PROVIDER: S-EPMC12862309 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature